💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
Syngene International Limited is an India-based integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors. The Company's services include…
Weekly engine runs — movement reflects the numbers, not analyst opinion.
A weak, stagnant business, reasonably priced.
Syngene International is scored on the general / industrial framework. It keeps a slim 8.3% of every rupee of sales as net profit. Those profits are backed by real cash — operating cash flow runs 2.89× reported profit. Free cash flow is worth about 0.3% of its market value.
Over the last 3 years revenue compounded at 5%/yr and profit at -12%/yr. Book value has grown 10%/yr. Return on equity is a weak 5.5%.
At 53× earnings, the stock sits at the 33rd percentile of its own 3.6-year range — the middle of where it has historically traded. Today's price already implies ~30%/yr earnings growth sustained for a decade — a demanding bar. The books come through clean — a forensic grade of A, and Altman puts distress risk in the safe zone.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | 90.5 | — | — |
| P/B | 3.47 | 2.11 | worse |
| EV/EBITDA | 22.96 | — | — |
| ROE | 5.47 | 10.49 | worse |
| ROCE | 7.06 | 12.9 | worse |
| ROA | 2.79 | 8.72 | worse |
| Quick Ratio | 1.29 | — | — |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Apollo Hospitals | 52.0 | 11.4 | 21.1% |
| Max Healthcare | 65.9 | 8.0 | 12.2% |
| Manipal Health Enterprises | 93.9 | 5.2 | 10.6% |
Revenue has grown every year across all 4 financial years shown. 5% CAGR — growing but slowly.
Revenue is outpacing profit (5% vs -12%) — costs are rising faster than the top line. The latest year saw a -36% swing — check if it's a one-off or structural.
Operating margin has compressed from 18% to 11% — costs or competition are eating into profitability.
ROE at 7% — modest; the capital isn't working hard. Capital efficiency declining — ROE down 6pp.
EPS dropped in the latest year despite possible profit changes — dilution or a profit dip could be at play. -12% EPS CAGR — this is the rate at which each share's claim on earnings is compounding.
Operating cash flow has been positive every year — the business generates real cash, not just accounting profit. Cash conversion at 2.9× PAT — earnings are well-backed by cash; strong accrual quality. Heavy investing spend every year, but operations generate enough to cover it — the business self-funds its growth.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue rose 13% sequentially — momentum is building. Run-rate fading — recent quarters 19% below earlier ones.
1 of 4 quarters loss-making — quarterly profitability is uneven. Profit jumped 458% QoQ — check if this is operating leverage or a one-off item. Quarterly net margins are expanding (2% → 4%) — profitability per rupee of revenue is improving.
How today's P/E compares to the stock's own historical range. Dashed line = the 3.6y median.
Promoter holding at 52.6% — majority control intact. FIIs trimmed 4.8pp — foreign money is rotating out. MF holding up 4.4pp — domestic institutional discovery underway.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.